• LAST PRICE
    0.5200
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.5100/ 44
  • Ask / Lots
    0.5700/ 10
  • Open / Previous Close
    --- / 0.5200
  • Day Range
    ---
  • 52 Week Range
    Low 0.4800
    High 2.8900
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.53
TimeVolumeDTC
02:45 ET20000.52
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
CanadaDTC
Defence Therapeutics Inc
24.5M
-2.0x
---
CanadaMDMA
Pharmala Biotech Holdings Inc
25.5M
-36.5x
---
CanadaRVX
Resverlogix Corp
15.3M
-0.9x
---
CanadaSONA
Sona Nanotech Inc
29.0M
-8.4x
---
CanadaSBM
Sirona Biochem Corp
19.7M
-7.2x
---
CanadaQNTM
Quantum BioPharma Ltd
13.7M
-0.3x
---
As of 2024-11-22

Company Information

Defence Therapeutics Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and engineering the radio-immuno-conjugate and antibody drug conjugates (ADC) products using its proprietary platform in addition to immune-oncology vaccines. Its principal business activity is the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The core of its therapeutics platform is the ACCUM technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. The Company is focused on research, development and advancement of the main products using its Accum technology, which include ADC targeting various cancers, Anti-cancer AccuTOX program, Mesenchymal stromal cell-based vaccine (ARM-X) targeting cancer and mRNA vaccination.

Contact Information

Headquarters
1680- 200 Burrard StreetVANCOUVER, BC, Canada V6C 3L6
Phone
514-947-2272
Fax
---

Executives

President, Chief Executive Officer, Director
Sebastien Plouffe
Chief Financial Officer, Director
P. Meagher
Vice President - Research & Development, Director
Moutih Rafei
Director
Svetlana Selivanova
Independent Director
Sarkis Meterissian

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$24.5M
Revenue (TTM)
$0.00
Shares Outstanding
47.1M
Defence Therapeutics Inc does not pay a dividend.
Beta
1.40
EPS
$-0.26
Book Value
$-0.08
P/E Ratio
-2.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.